Several studies tested the combined positive rate of BRAF mutation and TERT promoter mutations, and found all that patients with these 2 combined mutations were more likely to have a poor prognosis (distance metastasis, lymph node metastasis and so on) and outcomes (recurrence, TC-related mortality).[11,16,20,22] Xing found that coexisting BRAF V600E and TERT C228T mutations were more commonly associated with a poor outcome such as recurrence of PTC than they were individually.[30]. The gene discussed is BRAF; the disease is metastatic malignant neoplasm in the lymph nodes.